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Introduction {#sec001}
============

The ability of mutated cells to escape immune recognition is one of the major mechanism of tumor cells to become malignant. It takes many years from a precancerous lesion to transform into cancerous lesion. Multiple ongoing and continuous mutations eventually drive some clones of mutated cells to acquire the ability to escape immune recognition. The tumor cells able to escape immune surveillance by various mechanism. One of the mechanism of immune escape by tumor cells that is well studied is through expression of various immune checkpoint molecules. The interplay between the presence of various immune checkpoint molecules between host immune cells and tumor cells result in downplay of inflammatory signals.\[[@pone.0230449.ref001]\]

Nasopharyngeal cancer, which is tightly related with Epstein-Barr Virus (EBV) infection, has a distinct way from escaping immune surveillance. There are various viral products expressed in host cells that resulted in expansion of immunosuppressive cells, evasion of immune recognition by host major histocompatibility complex, and downregulation of various pro-inflammatory cytokines.\[[@pone.0230449.ref002]--[@pone.0230449.ref005]\] Apart from that, EBV viral proteins have also been implicated in upregulation of immune checkpoint molecule such as Programmed Cell Death Ligand 1 (PD-L1).\[[@pone.0230449.ref006]\] The expression of PD-L1 results in further downplay of immune attack, thereby it facilitates resistance free tumor progression.

Immune cells within the milieu of cancer cells have been shown to be associated with patient's prognosis in various types of cancer.\[[@pone.0230449.ref007]--[@pone.0230449.ref009]\] Various evidence suggesting a better prognosis in a rich infiltrating lymphocytes tumor microenvironment in nasopharyngeal cancer.\[[@pone.0230449.ref010],[@pone.0230449.ref011]\] However, there are also various reports suggesting a doubtful to a non-prognostic role of immune cells within nasopharyngeal tumor microenvironment.\[[@pone.0230449.ref012]--[@pone.0230449.ref014]\] Due to this conflicting evidence observed in nasopharyngeal cancer, there is a need to study the role of tumor infiltrating immune cells in a more straight forward manner with a more direct endpoint, thus eliminating many other confounding factors. In this study, we reported the relationship between local tumor infiltrating immune cells and local tumor volume.

Method {#sec002}
======

Patients selection and recruitment {#sec003}
----------------------------------

Twenty-five microscopically confirmed nasopharyngeal cancer patients were recruited consecutively from April to October 2019 from ENT oncology clinic in Cipto Mangunkusumo General Hospital, Jakarta. All patients were aged 18 and above. They all gave written consent to participate in this study. All patients underwent pathological reconfirmation by a senior pathologist and pre-treatment imaging. The pre-treatment imaging to asses local and regional tumor extension was either nasopharyngeal CT Scan or MRI Scan with scan area from at least the level of frontal sinus until supraclavicular. Chest X-Ray, bone scan, and abdominal ultrasound were conducted to assess metastatic disease. In case of doubtful lesion, additional imaging such as thoracic CT-Scan or abdominal CT-Scan or MRI was carried out for confirmation. All patients enrolled in this study did not have any prior cancer treatment. They also did not have any other severe diseases such hematological diseases or infectious diseases. They all had a routine peripheral blood count checked within a week prior from nasopharyngeal biopsy.

Immunohistochemistry (IHC) staining and evaluation {#sec004}
--------------------------------------------------

The process of PD-L1 IHC staining was performed in the Laboratory of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia. The paraffin embedded tissue of those confirmed NPC patients were cut until thickness of 3 μm. It was then deparaffinized with Xylol, rehydrated with alcohol 100%, 96%, and 70%. The slides were then pre-treated with Tris-EDTA on pH 9 in decloaking chamber at 94°C. It was further rinsed with Phosphate Buffer Saline (PBS), then stained with primary immunohistochemistry PD-L1 antibody (GeneTex: GTX104763). After stained with primary antibody, it was re-rinsed with PBS and counterstained with hematoxylin stain. Next, lithium carbonate solution was applied to the slides, then the slides were rehydrated again in alcohol 80%, 96%, and 100%. The stained was then cleared with xylol again and finally they were covered with glass slides.

Evaluation of PD-L1 staining was carried out based on the percentage of tumor cells that was stained positive on its cytomembrane. The percentage of positively stained tumor cells was then categorized into 5 scores, with score 0: ≤ 5%; score 1: 6 ≤ 25%; score 2: 26 to ≤ 50%; score 3: \>50% of PD-L1 positivity in tumor cells. The intensity of staining was not scored. Any intensity of staining as long as presence was calculated as positive stained cells. All the stained slides of PD-L1 IHC were evaluated until at least 10 fields of 400 times microscopic magnification independently by two different pathologists. In case of different scoring results by two pathologists, a consensus on final scoring was made after thorough review done together.

Tumor microenvironment evaluation {#sec005}
---------------------------------

Tumor microenvironment in the context of this study was defined as tumor infiltrating immune cells. It included all kind of immune cells. The evaluation of tumor infiltrating immune cells was based on a thin cut of a 3 μm paraffin embedded tissue biopsy specimen which was stained with hematoxylin eosin (HE) dye. The HE stained slides were evaluated for presence of nasopharyngeal cancer cells. Then the infiltrating immune cells surrounding the tumor cells were evaluated in 10 different representative fields under a 400 times magnification microscope independently by two different pathologists. The similar method as carried out in evaluation of IHC scoring was used in case of differences in initial independent scoring evaluation. The infiltrating immune cells for each patient's biopsy specimen were categorized and scored into 3 scores (1 = mild infiltration, 2 = moderate infiltration, 3 = heavy infiltration).

Tumor volume determination {#sec006}
--------------------------

Tumor volume was determined based pre-treatment 3D imaging, from either nasopharyngeal CT scan or MRI scan with contrast. The selected imaging was the one nearest to the date of nasopharyngeal tumor biopsy, with none more than 2 months apart. The tumor volume was determined by delineating the tumor in Eclipse^TM^ treatment planning system by 2 different radiation oncologists. The contours were done separately for local or primary tumor volume and nodal tumor volume from each patient. The final tumor contours were decided by consensus between those 2 radiation oncologists, then the tumor volumes were recorded.

Statistical analysis {#sec007}
--------------------

There were 3 groups of results which was stratified based on tumor infiltrating immune cells. The descriptive statistical analysis was done for all 3 groups. The figure following ± was denoted as standard deviation in this article, unless stated differently. The ANOVA statistical test was used to compare the means of those 3 groups. A p value of less than 0.05 was determined as statistical significance. The statistical test was carried out with SPSS software version 25.0.

Result {#sec008}
======

Patients and samples characteristics {#sec009}
------------------------------------

Twenty-five nasopharyngeal cancer patients were recruited. There were 5 (20%), 11 (44%), and 9 (36%) patients in mild, moderate, and heavy tumor infiltrating immune cells category, respectively. The H&E samples of different scores of tumor infiltrating immune cells were found in **[Fig 1A--1C](#pone.0230449.g001){ref-type="fig"}**. There was almost equal number of patients between age ≤50 years old and \>50 years old among the whole group. There were more males 19 (76%) than female in the whole group. The majority of patient was in stage IVA locally advanced stage. (see **[Table 1](#pone.0230449.t001){ref-type="table"}**) All patients had nasopharyngeal carcinoma WHO type 3 histology.

![Histopathology slide stained with Hematoxylin Eosin dye in 400 times magnification showing density of tumor infiltrating immune cells nearby tumor cells in nasopharyngeal cancer a) score 1 = mild infiltration; b) score 2 = moderate infiltration; c) score 3 = heavy infiltration.](pone.0230449.g001){#pone.0230449.g001}

10.1371/journal.pone.0230449.t001

###### Patient's characteristics segregated based on tumor infiltrating immune cells density score.

![](pone.0230449.t001){#pone.0230449.t001g}

                       Number of patients based on tumor infiltrating immune cells density score (percentage of total)                        
  -------------------- ------------------------------------------------------------------------------------------------- ---------- --------- -----------
  **Age**                                                                                                                                     
      ≤50 years old    2 (8%)                                                                                            6 (24%)    5 (20%)   13 (52%)
      \>50 years old   3 (12%)                                                                                           5 (20%)    4 (16%)   12 (48%)
  **Gender**                                                                                                                                  
      Male             3 (12%)                                                                                           10 (40%)   6 (24%)   19 (76%)
      Female           2 (8%)                                                                                            1 (4%)     3 (12%)   6 (24%)
  **Stadium**                                                                                                                                 
      III              0 (0%)                                                                                            2 (8%)     2 (8%)    4 (16%)
      IVA              1 (4%)                                                                                            7 (28%)    5 (20%)   13 (52%)
      IVB              4 (16%)                                                                                           2 (8%)     2 (8%)    8 (32%)
      Total            5 (20%)                                                                                           11 (44%)   9 (36%)   25 (100%)

All 25 biopsy samples were positively stained with IHC PD-L1 antibody. There was no sample with IHC PD-L1 score of 0 or \<5% positivity of cytomembranic PD-L1 staining. All samples from the whole group had at least above 6% positivity of cytomembranic PD-L1 staining, with majority had more than 50% positivity in PD-L1 staining. There were 2, 8, and 15 samples with IHC PD-L1 score of 1, 2, and 3 respectively. However, there was no relationship found between positivity of PD-L1 cytomembranic staining with tumor infiltrating immune cells scores in our samples. Several samples of different IHC PD-L1 staining were found in **[Fig 2A--2D](#pone.0230449.g002){ref-type="fig"}**.

![PD-L1 immunohistochemistry staining in 400 times magnification in nasopharyngeal cancer specimen a) Negative Control slide--no PD-L1 staining was observed on tumor cells; b) IHC PD-L1 in tumor cytomembranic cells---Score 1; c) IHC PD-L1 in tumor cytomembranic cells---Score 2; d) IHC PD-L1 in tumor cytomembranic cells---Score 3.](pone.0230449.g002){#pone.0230449.g002}

Relationship between tumor volume, tumor infiltrating immune cells and systemic immune cells {#sec010}
--------------------------------------------------------------------------------------------

There was an inverse relationship between local tumor infiltrating immune cells and local tumor volume. The mean local tumor volumes for each local tumor infiltrating immune cells score group were 181.92 cm^3^ ± 81.45 cm^3^, 117.13 cm^3^ ± 88.72 cm^3^, and 55.13 cm^3^ ± 25.06 cm^3^ for mild, moderate, and heavy infiltration score respectively (p = 0.013). In relatively larger local tumor volume patients, the tumor infiltrating immune cells were found to be sparser. The inverse was true with smaller local tumor volume patients having a denser tumor infiltrating immune cells. See **[Fig 3](#pone.0230449.g003){ref-type="fig"}**.

![Boxplot showing distribution and mean value of local tumor volume in nasopharyngeal cancer samples segregated based on local tumor infiltrating immune cells score density.](pone.0230449.g003){#pone.0230449.g003}

There was no relationship exist between local tumor infiltrating immune cells with nodal tumor volume and systemic immune cells. The mean nodal tumor volumes for each local tumor infiltrating immune cells score group were 56.76 cm^3^ ± 39.67 cm^3^, 104.71 cm^3^ ± 163.29 cm^3^, and 92.50 cm^3^ ± 162.27 cm^3^ for mild, moderate, and heavy infiltration score respectively (p = 0.838). The mean systemic leukocyte counts for those 3 group of patients segregated based on local tumor infiltrating immune cells score from 1 to 3 were 9,670 cells/μl ± 3,520 cells/μl, 9,210 cells/μl ± 2,341 cells/μl, and 8,885 cells/μl ± 3,440 cells/μl, respectively (p = 0.896). There was also no relationship exist between all the leukocyte subtypes from basophil, eosinophil, neutrophil, lymphocyte, and monocyte among all the 3 groups of patients that were segregated based on local tumor infiltrating immune cells score.

Discussion {#sec011}
==========

The PD-L1 positivity in nasopharyngeal cancer is common especially for those with EBV infection or WHO type 3 undifferentiated carcinoma histology.\[[@pone.0230449.ref013]\] The high expression of PD-L1 in nasopharyngeal cancer has been shown in some studies to confer favorable prognosis to overall survival or progression free survival.\[[@pone.0230449.ref012],[@pone.0230449.ref015]\] Nevertheless, there were also multiple studies shown that PD-L1 expression was not prognostic\[[@pone.0230449.ref012],[@pone.0230449.ref013]\] or even conferred negative prognosis\[[@pone.0230449.ref016]--[@pone.0230449.ref019]\] in nasopharyngeal cancer. A recent meta-analysis confirmed that there was conflicting results for the prognostic role of PD-L1 expression in nasopharyngeal cancer.\[[@pone.0230449.ref020]\]

There were various factors that might affect the conflicting evidence of this prognostic role of PD-L1 in nasopharyngeal cancer. The antibody assay to assess the PD-L1 expression and the scoring method to evaluate extensiveness of PD-L1 expression were very variable.\[[@pone.0230449.ref021]\] The endpoint measured such as overall survival and disease free survival were indeed an important measure of prognosis, however, those endpoints were affected by too many other factors. Probably, it would be necessary to look at a smaller scope and a more direct relationship for instance PD-L1 expression and the local tumor microenvironment, among other factors. Tumor microenvironment has been shown to be an important determinant of treatment success, thus affecting patient's prognosis.\[[@pone.0230449.ref010],[@pone.0230449.ref022]\]

In a complex and heterogeneous tumor, where the tumors were constantly evolving, the dynamic interaction between host immune cells and tumor cells were important. The PD-L1 expression in the primary tumor site could be different with the PD-L1 expression in other sites such as metastatic sites due to different local microenvironment.\[[@pone.0230449.ref023]\] In order to better determine prognosis, a single biomarker such as PD-L1 may not be sufficient. A combination of multiple factors including patient's characteristics, tumor microenvironment, and possibly some other genomic or molecular parameters would better predict prognosis and guide better treatment options.

In our study, we showed that local tumor infiltrating immune cells was prognostic for predicting local tumor extensiveness. We assessed the whole infiltrating immune cells, instead of just specific immune cells because all kind of immune cells play an important and integral role in tumor resistance by immune cells. Immune cells were composed of components of innate immunity and adaptive immunity, which together are required to elicit a full blown immune response. Adaptive immunity such as T cells with all its subsets have been known to play a major and critical role in resisting cancer cells growth by exerting direct cytotoxic effects.\[[@pone.0230449.ref024]\] However, T cells alone were not enough to suppress tumor growth, all the other components of innate immunity were required to assist in recognizing, recruiting, activating, and enhancing the effect of cytotoxic T cells.\[[@pone.0230449.ref025]\]

Components of innate immunity such as neutrophils, NK cells, dendritic cells, macrophages, and all the cytokines produced by those cells have been shown to hold an important role in cancer immunotherapy.\[[@pone.0230449.ref010],[@pone.0230449.ref022],[@pone.0230449.ref025]--[@pone.0230449.ref030]\] A recent study of tumor infiltrating neutrophils in colorectal cancer patients indicated a higher density of neutrophils surrounding the tumor cells was associated with better overall prognosis and better response toward chemotherapy.\[[@pone.0230449.ref027]\] All those evidence suggesting that evaluating the whole tumor infiltrating immune cells might have an important role in predicting patient's prognosis and selecting the treatment especially the novel immunotherapy.

Although local tumor infiltrating immune cells was only predictive for local tumor extensiveness only, it might still hold a role in predicting overall patient's prognosis if various other potentially prognostic factors were incorporated. This study also pointed out that utilizing a quite simple and inexpensive method of evaluating overall tumor infiltrating immune cells might also work. This method might serve as the basis for reporting tumor infiltrating immune cells in other trials. Furthermore, this finding could trigger further exploratory work on tumor and immune cells interaction, especially for nasopharyngeal cancer.

In case of systemic immune cells, this study did not find any relationship among different scores of local tumor infiltrating immune cells from various systemic immune cells indices. This implied that the number of circulating systemic immune cells was not directly related to density of local tumor infiltrating immune cells. There were data indicating that failure of immune cells trafficked to tumor microenvironment led to failure of treatment including immunotherapy.\[[@pone.0230449.ref031]\] Nevertheless, there were studies reported prognostic role of circulating lymphocyte and neutrophil to immunotherapy response.\[[@pone.0230449.ref032],[@pone.0230449.ref033]\] Therefore, a more thorough understanding is required to study and explore the role of systemic immune cells in affecting treatment response and finding ways to potentially increase T cells homing to tumor microenvironment.

Conclusion {#sec012}
==========

The local tumor infiltrating immune cells were related to local tumor extensiveness in PD-L1 positive nasopharyngeal cancer patients, with denser infiltration resulted in smaller local tumor volume. Evaluating overall tumor infiltrating immune cells might be important and could serve as a simple and predictive marker for determining prognosis and possibly guiding treatment.
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======================
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In this manuscript, the authors found that the PD-L1 was highly expressed in 25 NPC samples. They also revealed that denser local tumor infiltrating immune cells population have relatively much small local tumor volume. Thus, tumor infiltrating immune cells play an important role in tumor progression. The detection of tumor infiltrating immune cells may offer valuable prognostic information for NPC. This manuscript is well-written and the figures are well-presented. I only have one comment. I wonder if these NPC patents are receiving chemotherapy during this project. Chemotherapy or other therapies may have an impact on the distribution and density of tumor infiltrating immune cells. The authors should clarify this in the manuscript.
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1.Local tumor volume can be measured by CT or MRI scan exactly. There is no need to \"predict\" it. In this research the authors indicated the relationship between tumor volume and its microenviroment, changing the title into, for example, \"Tumor microenvironment charactaristics in different tumor extensiveness in PD-L1 positive nasopharyngeal cancer\" would more appropriate.

Thank you for the comment and suggestion. Yes it is true that we can obtain exact tumor volume by CR or MRI scan. Your suggestion "Tumor microenvironment characteristics in different tumor extensiveness in PD-L1 positive nasopharyngeal cancer\" was great, however, the term "in different tumor extensiveness" could be connoted by some people as different disease stages. While actually in our study we used exact tumor volume.
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2.Did the enrolled patients received any treatment before biopsy? Medical treatment can influence the tumor progression and its microenviroment and further affect the final results.

No, all patients did not receive any prior treatment. We have revised and included a clear statement in our revised manuscript that all subjects enrolled in our study did not ever received any kind of treatment before.

3.In line 153

Did the enrolled patients have any hematological disease or infectious complications when taking peripheral blood count? These factors can affect the peripheral blood components and authors should illuminate this.

No, all patients enrolled did not have any hematological disease nor infections. The routine peripheral blood checks was part of our institution protocol. All patients would have the blood checked before biopsy and every week during treatment. Furthermore, the patient would not be biopsied if they had any kind of infection. We have also included a statement in our revised manuscript stating that all patients enrolled did not have any other severe diseases such hematological diseases or infectious diseases.
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It may be insufficient to use HE dye to evaluate tumor infiltrating immune cells level because it is too subjective. CD45 is widely expressed in all kinds of immune cells, so I suggest that CD45 staining is need to help evaluating the infiltrating level.
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Yes, we meant selected imaging. We have revised it in our revised manuscript. Thanks for point it out for us.

6.PD-L1 is an important immunosupression molecular. So what is the relationship between PD-L1 expression and tumor infiltrating immune cells? In other kinds of cancers, PD-L1 often has higher expression in \"hot tumor\".

There was no relationship found between PD-L1 expression and tumor infiltrating immune cells in our study. We were aware that some tumor did have relationship exist between those two. We have added a statement in our revised manuscript describing the absence of relationship between PD-L1 and tumor infiltrating immune cells in our NPC samples.
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